Needs institutional support.Also, the market is probably factoring in a CR within 12 months & the business model hasn't been validated (no royalties or milestones).
Once we see a milestone from TEVA or Edding that will start to move the needle. And if Artimist can go or another 001H deal lands, it will turn.
Management have gotten on a roll, knocked out 3 deals in a quarter. It will get there.
Suda signs deal with $936bn pharma company, page-5
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
